A Study of LY900014 Formulation in Healthy Participants
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is
administered by injection under the skin of the abdomen. The study will be conducted in
healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of
different doses of LY900014 on blood sugar levels. Side effects and tolerability will be
documented. The study will last about 6 to 7 weeks for each participant, including screening
and follow up. Screening is required within 28 days prior to entering the study.